Controlling cytokine signaling by constitutive inhibitors.

[1]  J. Sadler,et al.  Variants of a cloned synthetic lactose operator. I. A palindromic dimer lactose operator derived from one stand of the cloned 40-base pair operator. , 1981, Gene.

[2]  D. Chang,et al.  Inhibition of Stat1-mediated gene activation by PIAS1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. Feng,et al.  Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Feng.  Shp-2 tyrosine phosphatase: signaling one cell or many. , 1999, Experimental cell research.

[5]  A. Yoshimura,et al.  The Jak-Stat pathway in normal and perturbed hematopoiesis. , 2000, Blood.

[6]  C. Maroun,et al.  The Tyrosine Phosphatase SHP-2 Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase , 2000, Molecular and Cellular Biology.

[7]  M. Wasik,et al.  Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. , 2000, The American journal of pathology.

[8]  Peter Jackson,et al.  The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. , 2000, Trends in cell biology.

[9]  J. O’Shea,et al.  Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation , 1999, Arthritis research.

[10]  W. Birchmeier,et al.  Coupling of Gab1 to C-Met, Grb2, and Shp2 Mediates Biological Responses , 2000, The Journal of cell biology.

[11]  T. Magnuson,et al.  Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis , 2000, Nature Genetics.

[12]  G. Schlüter,et al.  Evidence for translational repression of the SOCS-1 major open reading frame by an upstream open reading frame. , 2000, Biochemical and biophysical research communications.

[13]  B. Gao,et al.  IL‐10 attenuates IFN‐α‐activated STAT1 in the liver: involvement of SOCS2 and SOCS3 , 2000 .

[14]  F. Melchior,et al.  SUMO--nonclassical ubiquitin. , 2000, Annual review of cell and developmental biology.

[15]  O. Silvennoinen,et al.  ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. , 2000, Molecular endocrinology.

[16]  Yan Liu,et al.  Scaffolding Protein Gab2 Mediates Differentiation Signaling Downstream of Fms Receptor Tyrosine Kinase , 2001, Molecular and Cellular Biology.

[17]  C. Pickart,et al.  Ubiquitin enters the new millennium. , 2001, Molecular cell.

[18]  M. Kubo,et al.  SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. , 2002, Immunity.

[19]  Alberto Martin,et al.  Molecular mechanisms underlying SHP-1 gene expression. , 2002, European journal of biochemistry.

[20]  R. DePinho,et al.  STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. , 2002, Immunity.

[21]  Kenji Nakanishi,et al.  SOCS-1 participates in negative regulation of LPS responses. , 2002, Immunity.

[22]  S. Layé,et al.  In vivo Activation of the Interleukin-6 Receptor/gp130 Signaling Pathway in Pituitary Corticotropes of Lipopolysaccharide-Treated Rats , 2003, Neuroendocrinology.

[23]  Jens Schneider-Mergener,et al.  SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130* , 2003, The Journal of Biological Chemistry.

[24]  Lijun Liu,et al.  The function of the protein tyrosine phosphatase SHP-1 in cancer. , 2003, Gene.

[25]  T. Arora,et al.  PIASx Is a Transcriptional Co-repressor of Signal Transducer and Activator of Transcription 4* , 2003, Journal of Biological Chemistry.

[26]  Fang Liu,et al.  Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3) , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Müller,et al.  PIAS/SUMO: new partners in transcriptional regulation , 2003, Cellular and Molecular Life Sciences CMLS.

[28]  J. Toppari,et al.  Identification of a short PIASx gene promoter that directs male germ cell-specific transcription in vivo. , 2003, Biochemical and biophysical research communications.

[29]  M. Bencherif,et al.  Angiotensin II Blocks Nicotine-Mediated Neuroprotection against β-Amyloid (1-42) via Activation of the Tyrosine Phosphatase SHP-1 , 2003, The Journal of Neuroscience.

[30]  M. Kubo,et al.  Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. , 2003, Immunity.

[31]  K. Shuai,et al.  Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.

[32]  Richard S. Rogers,et al.  SUMO Modification of STAT1 and Its Role in PIAS-mediated Inhibition of Gene Activation* , 2003, Journal of Biological Chemistry.

[33]  A. Ryo,et al.  Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. , 2003, Molecular cell.

[34]  K. Uematsu,et al.  Cloning and characterization of a functional promoter of the human SOCS-3 gene , 2003 .

[35]  Lei Shen,et al.  Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity , 2004, Nature Biotechnology.

[36]  C. June,et al.  SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.

[37]  Jie Zhao,et al.  Loss of SHP-1 phosphatase alters cytokine expression in the mouse hindbrain following cochlear ablation. , 2004, Cytokine.

[38]  G. Kapoor,et al.  Distinct Domains in the SHP-2 Phosphatase Differentially Regulate Epidermal Growth Factor Receptor/NF-κB Activation through Gab1 in Glioblastoma Cells , 2004, Molecular and Cellular Biology.

[39]  Hong Wu,et al.  PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity , 2004, Nature Immunology.

[40]  Liming Wang,et al.  Differential PIAS3 expression in human malignancy. , 2004, Oncology reports.

[41]  J. Johnston,et al.  SOCS: role in inflammation, allergy and homeostasis. , 2004, Trends in immunology.

[42]  H. Christofk,et al.  Protein Inhibitor of Activated STAT Y (PIASy) and a Splice Variant Lacking Exon 6 Enhance Sumoylation but Are Not Essential for Embryogenesis and Adult Life , 2004, Molecular and Cellular Biology.

[43]  M. Loh,et al.  Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. , 2004, Blood.

[44]  B. Gelb,et al.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. , 2004, Blood.

[45]  Soo Young Lee,et al.  PIAS3 Suppresses NF-κB-mediated Transcription by Interacting with the p65/RelA Subunit* , 2004, Journal of Biological Chemistry.

[46]  M. Loh,et al.  PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group , 2004, Leukemia.

[47]  M. Gross,et al.  PIASy-mediated repression of the androgen receptor is independent of sumoylation , 2004, Oncogene.

[48]  P. Massa,et al.  Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP‐1‐deficient mice , 2004, Journal of neuroscience research.

[49]  E. Kremmer,et al.  PIASy-Deficient Mice Display Modest Defects in IFN and Wnt Signaling1 , 2004, The Journal of Immunology.

[50]  Molecular cloning and characterization of a novel splicing variant of PIASx. , 2004, Acta pharmacologica Sinica.

[51]  C. Geisler,et al.  Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNα , 2005, Leukemia.